Catalent Announces First Quarter Fiscal Year 2017 Earnings Conference Webcast

- October 13th, 2016

The Company’s management will host a webcast to discuss the results at 4:45 p.m. ET on November 7, 2016.

Catalent, Inc. (NYSE: CTLT) (“Catalent”), the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that it will release financial results for the first quarter of fiscal year 2017 ended September 30, 2016, after the market close on Monday, November 7, 2016. The Company’s management will host a webcast to discuss the results at 4:45 p.m. ET on the same day.
Catalent invites all interested parties to listen to the webcast, which
will be accessible through Catalent’s website at http://investor.catalent.com.
A supplemental slide presentation will also be available in the
“Investors” section of Catalent’s website prior to the start of the
webcast.
The webcast replay, along with the supplemental slides, will be
available for 90 days in the “Investors” section at www.catalent.com.
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT) is the leading global provider of advanced
delivery technologies and development solutions for drugs, biologics and
consumer health products. With over 80 years serving the industry,
Catalent has proven expertise in bringing more customer products to
market faster, enhancing product performance and ensuring reliable
clinical and commercial product supply. Catalent employs approximately
9,200 people, including over 1,000 scientists, at more than 30
facilities across 5 continents and in fiscal 2016 generated $1.85
billion in annual revenue. Catalent is headquartered in Somerset, N.J.
For more information, please visit www.catalent.com.
More products. Better treatments. Reliably supplied.™

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Leave a Reply